Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

PARP inhibitors for metastatic breast cancer

BGICC 2020

9 - 10 Jan 2020

Published: 29 Jan 2020

Views: 957

Rating:

Save

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Prof Banu Arun spoke to ecancer at the BGICC 2020 conference in Cairo, Egypt about PARP inhibitors for metastatic breast cancer.

She highlights some of the recent trials that have been testing PARP inhibitors in this setting.

Prof Arun finalises by suggesting how these trials may develop, particularly looking at combination of platinums.

Related Videos

SABCS 2024: Highlights in breast cancer genomic testing

Prof Matteo Lambertini and Prof Virginia Kaklamani

SABCS 2024: Highlights in breast cancer genomic testing ( Prof Matteo Lambertini and Prof Virginia Kaklamani )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron...

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer

Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA

The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer ( Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer